Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Eva Fernvik, PhD

ViiV Healthcare, Sweden

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Employee

Poster(s):

(P-574) Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT